Q2 2026 saw EBITDA improvement and stable sales, with strong growth outside Germany offsetting declines in the German market due to lower ICU occupancy. NDA for US approval was submitted, and the Early Access Program is underway, positioning for significant US market expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.